Research progress of FcRn antagonists in the treatment of IgG-mediated neuroimmune diseases
10.3969/j.issn.1002-0152.2025.01.009
- VernacularTitle:FcRn拮抗剂在IgG介导的神经免疫性疾病治疗中研究进展
- Author:
Xiaohuan ZHU
1
;
Wenshuang ZENG
1
;
Haibing XIAO
1
;
Huiting LIN
1
;
Lina LI
1
Author Information
1. 香港大学深圳医院神经内科(深圳 518053)
- Publication Type:Journal Article
- Keywords:
Neonatal Fc receptor;
FcRn antagonist;
Immunoglobulin G;
Neuroimmune disease
- From:
Chinese Journal of Nervous and Mental Diseases
2025;51(1):48-53
- CountryChina
- Language:Chinese
-
Abstract:
The neonatal Fc receptor(FcRn)prolongs the half-life of immunoglobulin G(IgG)and promotes its recycling by binding to and making it an important receptor for maintaining serum IgG homeostasis.However,the abnormal accumulation of pathogenic IgG is closely related to the occurrence of various neuroimmune diseases.FcRn antagonists can significantly reduce the level of pathogenic IgG by blocking the binding of FcRn to IgG,thereby effectively alleviating the clinical symptoms of related diseases.As an emerging targeted therapeutic drug,FcRn antagonists have shown their potential in treating IgG-mediated neuroimmune diseases.This article summarizes the mechanism of action,types and clinical research progress of FcRn antagonists with the aim of providing new ideas for the precise treatment of IgG-mediated neuroimmune diseases.Future research should focus on the long-term safety of drugs,expansion of indications and individualized treatment strategies to further enhance their clinical application value.
